| Literature DB >> 34162410 |
Hongbo Guo1,2,3, Jiazhou Wang1,2,3, Xiang Xia1,2,3, Yang Zhong1,2,3, Jiayuan Peng1,2,3, Zhen Zhang4,5,6, Weigang Hu7,8.
Abstract
PURPOSE: To investigate the dosimetric impact of deep learning-based auto-segmentation of organs at risk (OARs) on nasopharyngeal and rectal cancer. METHODS AND MATERIALS: Twenty patients, including ten nasopharyngeal carcinoma (NPC) patients and ten rectal cancer patients, who received radiotherapy in our department were enrolled in this study. Two deep learning-based auto-segmentation systems, including an in-house developed system (FD) and a commercial product (UIH), were used to generate two auto-segmented OARs sets (OAR_FD and OAR_UIH). Treatment plans based on auto-segmented OARs and following our clinical requirements were generated for each patient on each OARs sets (Plan_FD and Plan_UIH). Geometric metrics (Hausdorff distance (HD), mean distance to agreement (MDA), the Dice similarity coefficient (DICE) and the Jaccard index) were calculated for geometric evaluation. The dosimetric impact was evaluated by comparing Plan_FD and Plan_UIH to original clinically approved plans (Plan_Manual) with dose-volume metrics and 3D gamma analysis. Spearman's correlation analysis was performed to investigate the correlation between dosimetric difference and geometric metrics.Entities:
Keywords: Auto-segmentation; Deep learning; Dosimetric; Treatment planning
Mesh:
Year: 2021 PMID: 34162410 PMCID: PMC8220801 DOI: 10.1186/s13014-021-01837-y
Source DB: PubMed Journal: Radiat Oncol ISSN: 1748-717X Impact factor: 3.481
Fig. 1The workflow of this study
The target and the OARs constraint functions and dosimetric evaluation metrics
| Site | Target/OARs | Prescription | Constraints or objectives | Dosimetric evaluation |
|---|---|---|---|---|
| NPC | PTV70.4 | 70.4 Gy/32 F | D95 > Prescription, D2 < 110% Prescription, uniform dose = Prescription | V100, D95, D2 |
| PTV66 | 66 Gy/32 F | |||
| PTV60 | 60 Gy/32 F | |||
| PTV54 | 54 Gy/32 F | |||
| Eyes | / | Max Dose < 50 Gy | Max Dose | |
| Lens | / | Max Dose < 25 Gy | Max Dose | |
| Brainstem | / | Max Dose < 54 Gy | Max Dose | |
| Temporal lobes | / | Max Dose < 65 Gy, V60 < 1% | Max Dose | |
| Spinal cord | / | Max Dose < 45 Gy | Max Dose | |
| Optic nerves | / | Max Dose < 54 Gy | Max Dose | |
| Larynx | / | Mean Dose < 45 Gy | Mean Dose | |
| Parotid | / | Mean Dose < 26 Gy | Mean Dose, V30 | |
| Oral cavity | / | Mean Dose < 40 Gy | Mean Dose | |
| Temporomandibular joints | / | Max Dose < 70 Gy | Not evaluated | |
| Chiasm | / | Max Dose < 54 Gy | Not evaluated | |
| Rectum | PTV | 50 Gy/25 F | D95 > Prescription, D2 < 110% Prescription, uniform dose = Prescription | V100, D95, D2 |
| Femoral heads | / | V40 < 40%, Max Dose < 50 Gy | Mean Dose | |
| Bladder | / | V40 < 50% | Mean Dose, V40 |
Fig. 2Different dosimetric evaluation methods between this study and others
Fig. 3Geometric evaluation results of auto-segmentation. a The DICE; b The mean distance to agreement (MDA); c The Jaccard; d The Hausdorff distance (HD)
Fig. 4An example of rectal cancer patient. a Manual OARs; b FD OARs; c UIH OARs; d Contour comparison; e Plan_Manual dose distribution; f Plan_FD dose distribution; g Plan_UIH dose distribution; h PTV contour; i Plan_FD with manual OARs; j Plan_UIH with manual OARs; k 3D Gamma analysis of Plan_FD; red color represents gamma index > 1; l 3D Gamma analysis of Plan_UIH, red color represents gamma index > 1
Summary of the PTV dosimetry parameters of the reoptimized treatment plans (Plan_FD and Plan_UIH) and the original clinical treatment plans (Plan_Manual). All of the values are reported as the mean ± standard deviation
| Site/structure | Dosimetric Indices | Plan | Value | Comparison (paired t test) |
|---|---|---|---|---|
| Rectal/PTV | V100 (%) | Manual | 97.41 ± 1.91 | – |
| FD | 96.37 ± 2.98 | |||
| UIH | 96.49 ± 2.72 | |||
| D95 (cGy) | Manual | 5088 ± 77 | – | |
| FD | 5028 ± 66 | |||
| UIH | 5042 ± 70 | |||
| D2 (cGy) | Manual | 5349 ± 177 | – | |
| FD | 5384 ± 167 | |||
| UIH | 5383 ± 160 | |||
| Gamma Pass Rate (3 mm/3%) | FD | 97.16 ± 2.43 | – | |
| UIH | 97.20 ± 2.34 | – | ||
| Conformity Index (CI) | Manual | 0.78 ± 0.23 | – | |
| FD | 0.78 ± 0.23 | |||
| UIH | 0.78 ± 0.23 | |||
| Homogeneity Index (HI) | Manual | 0.10 ± 0.08 | – | |
| FD | 0.10 ± 0.06 | |||
| UIH | 0.10 ± 0.06 | |||
| NPC/PTV70.4 | V100 (%) | Manual | 93.39 ± 0.94 | – |
| FD | 92.75 ± 2.03 | |||
| UIH | 92.28 ± 2.00 | |||
| D95 (cGy) | Manual | 6984 ± 25 | – | |
| FD | 6978 ± 31 | |||
| UIH | 6962 ± 32 | |||
| D2 (cGy) | Manual | 7425 ± 270 | – | |
| FD | 7445 ± 287 | |||
| UIH | 7423 ± 276 | |||
| Gamma Pass Rate (3 mm/3%) | FD | 99.20 ± 1.07 | – | |
| UIH | 96.35 ± 2.34 | – | ||
| Conformity Index (CI) | Manual | 0.72 ± 0.05 | – | |
| FD | 0.70 ± 0.04 | |||
| UIH | 0.70 ± 0.06 | |||
| Homogeneity Index (HI) | Manual | 0.12 ± 0.05 | – | |
| FD | 0.12 ± 0.05 | |||
| UIH | 0.12 ± 0.04 |
Summary of the OARs dosimetry parameters of the reoptimized treatment plans (Plan_FD and Plan_UIH) and the original clinical treatment plans (Plan_Manual). All of the values are reported as the mean ± standard deviation
| Site | Structure | Dose-volume metrics | Plan | Value | Comparison (paired t test) |
|---|---|---|---|---|---|
| Rectal | Bladder | V40 (%) | Manual | 43.45 ± 26.96 | – |
| FD | 43.73 ± 26.28 | ||||
| UIH | 41.76 ± 26.55 | ||||
| Dmean (cGy) | Manual | 3476 ± 1281 | – | ||
| FD | 3464 ± 1264 | ||||
| UIH | 3427 ± 1262 | ||||
| Femoral head_L | Dmean (cGy) | Manual | 2199 ± 773 | – | |
| FD | 2160 ± 718 | ||||
| UIH | 2185 ± 824 | ||||
| Femoral head_R | Dmean (cGy) | Manual | 2130 ± 755 | – | |
| FD | 2085 ± 712 | ||||
| UIH | 2153 ± 819 | ||||
| NPC | Eye_L | Dmax (cGy) | Manual | 2199 ± 1175 | – |
| FD | 2135 ± 1265 | ||||
| UIH | 2153 ± 1168 | ||||
| Eye_R | Dmax (cGy) | Manual | 2441 ± 1892 | – | |
| FD | 2386 ± 1906 | ||||
| UIH | 2463 ± 1906 | ||||
| Spinal cord | Dmax (cGy) | Manual | 4261 ± 161 | – | |
| FD | 4227 ± 191 | ||||
| UIH | 4251 ± 281 | ||||
| Brainstem | Dmax (cGy) | Manual | 5578 ± 803 | – | |
| FD | 5528 ± 717 | ||||
| UIH | 5551 ± 706 | ||||
| Parotid_L | V30 (%) | Manual | 57.78 ± 25.86 | – | |
| FD | 58.07 ± 26.73 | ||||
| UIH | 57.37 ± 26.36 | ||||
| Dmean (cGy) | Manual | 4365 ± 926 | – | ||
| FD | 4381 ± 959 | ||||
| UIH | 4307 ± 951 | ||||
| Parotid_R | V30 (%) | Manual | 55.53 ± 23.68 | – | |
| FD | 55.16 ± 23.82 | ||||
| UIH | 53.96 ± 24.88 | ||||
| Dmean (cGy) | Manual | 4060 ± 508 | – | ||
| FD | 4057 ± 538 | ||||
| UIH | 3936 ± 608 | ||||
| Len_L | Dmax (cGy) | Manual | 592 ± 390 | – | |
| FD | 591 ± 387 | ||||
| UIH | 588 ± 379 | ||||
| Len_R | Dmax (cGy) | Manual | 568 ± 385 | – | |
| FD | 529 ± 279 | ||||
| UIH | 529 ± 281 | ||||
| Optic nerve_L | Dmax (cGy) | Manual | 3551 ± 2224 | – | |
| FD | 3493 ± 2276 | ||||
| UIH | 3525 ± 2206 | ||||
| Optic nerve_R | Dmax (cGy) | Manual | 3612 ± 2115 | – | |
| FD | 3617 ± 2119 | ||||
| UIH | 3784 ± 2113 | ||||
| Temporal lobe_L | Dmax (cGy) | Manual | 6376 ± 2126 | – | |
| FD | 6444 ± 2156 | ||||
| UIH | 6397 ± 2125 | ||||
| Temporal lobe_R | Dmax (cGy) | Manual | 6430 ± 2143 | – | |
| FD | 6442 ± 2130 | ||||
| UIH | 6390 ± 2123 | ||||
| Oral cavity | Dmean (cGy) | Manual | 3933 ± 551 | – | |
| FD | 3928 ± 566 | ||||
| UIH | 3895 ± 565 | ||||
| Larynx | Dmean (cGy) | Manual | 3829 ± 153 | – | |
| FD | 3809 ± 169 | ||||
| UIH | 3798 ± 195 |
Fig. 5The dose-volume histogram (DVH) of Plan_Manual, Plan_FD and Plan_UIH for an representative rectal cancer cases
The correlation between dosimetric differences and the geometric metrics
| Site | Structure | Dosimetric differences | Geometric metrics | Correlation analysis |
|---|---|---|---|---|
| Rectal | Bladder | ΔV40 (%) | DICE | |
| MDA | ||||
| Jaccard | ||||
| HD | ||||
| ΔDmean (cGy) | DICE | |||
| MDA | ||||
| Jaccard | ||||
| HD | ||||
| Femoral heads | ΔDmean (cGy) | DICE | ||
| MDA | ||||
| Jaccard | ||||
| HD | ||||
| NPC | Eyes | ΔDmax (cGy) | DICE | |
| MDA | ||||
| Jaccard | ||||
| HD | ||||
| Spinal cord | ΔDmax (cGy) | DICE | ||
| MDA | ||||
| Jaccard | ||||
| HD | ||||
| Brainstem | ΔDmax (cGy) | DICE | ||
| MDA | ||||
| Jaccard | ||||
| HD | ||||
| Parotids | ΔV30 (%) | DICE | ||
| MDA | ||||
| Jaccard | ||||
| HD | ||||
| ΔDmean (cGy) | DICE | |||
| MDA | ||||
| Jaccard | ||||
| HD | ||||
| Lens | ΔDmax (cGy) | DICE | ||
| MDA | ||||
| Jaccard | ||||
| HD | ||||
| Optic nerves | ΔDmax (cGy) | DICE | ||
| MDA | ||||
| Jaccard | ||||
| HD | ||||
| Temporal lobes | ΔDmax (cGy) | DICE | ||
| MDA | ||||
| Jaccard | ||||
| HD | ||||
| Oral cavity | ΔDmean (cGy) | DICE | ||
| MDA | ||||
| Jaccard | ||||
| HD | ||||
| Larynx | ΔDmean (cGy) | DICE | ||
| MDA | ||||
| Jaccard | ||||
| HD |